〔Abstract〕 Objective To analyze the clinical effect of compound brain peptide ganglioside on stroke rehabilitation. Methods The clinical data of 244 stroke patients treated and treated by China Rehabilitation Research Center from January 2018 to May 2022 were retrospectively analyzed, and the patients were randomly divided into treated group and untreated group according to whether compound cerebral peptide ganglioside injection was used, with 122 cases in each group. The clinical efficacy and rehabilitation status of the patients in the two groups were compared, and the factors affecting the recovery of stroke treated by compound cerebral peptide ganglioside were analyzed. Results The total effective rate of the treated group was 85.24 %, which was significantly higher than that of the untreated group (72.13 %), and the difference was statistically significant (P < 0.05). After treatment, the score of Montreal cognitive assessment scale (MoCA) in the treated group was higher than that in the untreated group, and the score of daily living scale (ADL) was lower than that in the untreated group, with statistical significance (P < 0.05). There was no significant difference in the National Institutes of Health stroke scale (NIHSS) between the two groups of male patients (P > 0.05). After treatment, NIHSS score of female patients in the treated group was lower than that in the untreated group, and the difference was statistically significant (P < 0.05). Conclusion In the treatment of cerebral apoplexy patients, compound cerebral peptide ganglioside can improve the rehabilitation effect of patients, and the recovery effect of women is better than that of men.